Relief Therapeutics Holding AG (RLFTF)

[clambottler]

JAVITT'S BIG SPIN - Part 4

You can see now that the media is catching on


NeuroRx Says COVID-19 Drug Improves Survival If Overstretched ICUs Excluded
Will Seek EUA Shortly


01 Apr 2021
NEWS


Andrew McConaghie
[e-mail]

Executive Summary

Therapy shows some promise in helping COVID-19 respiratory failure patients but the US FDA may question company’s data cut.




https://scrip.pharmaintelligence.informa.com/SC144107/NeuroRx-Says-COVID-19-Drug-Improves-Survival-If-Overstretched-ICUs-Excluded


============================================
Therapy shows some promise in helping COVID-19 respiratory failure patients but the US FDA may question company’s data cut.

====================================

Reminder:
Javitt SSRN QUOTEs:

" Setting: Ten US-based acute care hospitals, which included 4 tertiary care teaching hospitals and 6 regional hospitals. "


" Participants: 196 patients with PCR+ Critical COVID-19
treated with High Flow Nasal Cannula (HFNC: n=127)
Non-Invasive Ventilation (NIV: n=32)
or Mechanical Ventilation (MV: n=36). "

===============================================

Participants: 196 patients

REMOVED 32 patients treated with Non-Invasive Ventilation (NIV: n=32)

REMOVED 36 patients treated with Mechanical Ventilation (MV: n=36).

127 patients treated with High Flow Nasal Cannula (HFNC: n=127)

REMOVED ALL patients treated at " 6 regional hospitals "

Data / analysis = claim of significance provided on patients treated at
" 4 tertiary care teaching hospitals "

NUMBER of patients treated at " 4 tertiary care teaching hospitals "
NOT PROVIDED


==============> many of these hospitals have an inherent bias when treating patients on drug, they just cannot help themselves, it is human nature, nothing mischievious / intentional <==============


My Bet Opinion Hunch Surmise Guess - Javitt knows this Javitt knows this all too well

There is no chance of EUA or maybe a 2% chance
and there is 100 % chance that NO APPROVAL on this trial - its impossible.


Unfortunately the trial for ' approval ' purposes is a disaster -

We do not know how much of a disaster because:

JAVITT removed the 6 REGIONAL HOSPITAL data - so we do not know how many patients he removed and have no idea how those patients fared

and We do NOT KNOW how many patients were treated at the " 4 tertiary care teaching hospitals " -
how many received aviptadil/zyesami
though presume they were enrolled 2:1 per protocol.


In Short - a do over - will have to wait another 6 months perhaps more for the I Spy or other trial results.


Good Luck to All
xxx.
xx.
x.